The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Suboptimal clinician awareness of appropriate NTRK fusion testing and TRK inhibitor use in solid tumors.
 
Ryan P. Topping
No Relationships to Disclose
 
Krista Marcello
No Relationships to Disclose
 
Terrence Fagan
No Relationships to Disclose
 
Timothy A. Quill
No Relationships to Disclose
 
Todd Michael Bauer
Employment - Tennessee Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Exelixis; Foundation Medicine; Guardant Health; Ignyta (Inst); Loxo; Moderna Therapeutics (Inst); Pfizer; Pfizer (Inst)
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Lilly
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Immunocore (Inst); Immunogen (Inst); Incyte (Inst); Jacobio (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo (Inst); MabVax (Inst); MedImmune (Inst); medpacto (Inst); Merck (Inst); Merrimack (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Onyx (Inst); Peleton (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Principa Biopharma (Inst); Roche (Inst); Sanofi (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Top Alliance BioScience (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Celgene; Clovis Oncology; EMD Serono; Genentech; Lilly; Merck; Novartis; Pfizer; Pharmacyclics; Sysmex
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Archer; AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; EMD Serono/Merck; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; Melendi; Monopteros Therapeutics; Monopteros Therapeutics; MORE Health; Novartis; Pfizer; Remedica; Repare Therapeutics; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
George D. Demetri
Leadership - Blueprint Medicines; Merrimack; Translate BIO
Stock and Other Ownership Interests - Bessor Pharma; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Champions Oncology; Erasca, Inc; G1 Therapeutics; Merrimack; Relay Therapeutics; Translate BIO
Consulting or Advisory Role - Acrivon Therapeutics; Adaptimmune; Arsenal Capital; Bayer; Blueprint Medicines; Caprion/HistoGeneX; Caris Life Sciences; Daiichi Sankyo; EMD Serono; Epizyme; G1 Therapeutics; ICON Clinical Research; Ignyta; Janssen Oncology; Loxo; Medscape; Mirati Therapeutics; MJH Associates; Novartis; Pfizer; PharmaMar; Polaris; Relay Therapeutics; Roche/Genentech; Sanofi; WIRB-Copernicus Group; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); AbbVie (Inst); Adaptimmune (Inst); Bayer (Inst); Daiichi Sankyo (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Janssen Oncology (Inst); Loxo (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber after license between Dana-Farber and Novartis
Expert Testimony - Epizyme
Travel, Accommodations, Expenses - Alexandria Real-Estate Summit
(OPTIONAL) Uncompensated Relationships - AACR; Alexandria Real-Estate Summit; McCann Health